Seal Rock eligible to
receive payments up to €100 million, including regulatory,
clinical, and commercial milestone payments, plus tiered
royalties
SEATTLE, May 31, 2023
/PRNewswire/ -- Seal Rock Therapeutics, Inc., a clinical stage
company developing first-in-class and best-in-class kinase
inhibitors, today announced it has entered into an out-licensing
agreement with GENFIT (Nasdaq and Euronext: GNFT) for the
development of an injectable formulation of SRT-015 for acute liver
disease, including Acute-on-Chronic Liver Failure (ACLF).
Under the agreement, Seal Rock Therapeutics is eligible for
payments up to €100 million, including regulatory, clinical, and
commercial milestone payments, plus tiered royalties.
SRT-015, a highly optimized, second generation, liver-selective
inhibitor of Apoptosis Signal-reducing Kinase 1 (ASK1). It is being
developed by Seal Rock Therapeutics, in an oral formulation, as a
treatment for severe acute alcoholic hepatitis as well as orphan
liver diseases and NASH.
"We're excited to announce this licensing deal with GENFIT that
will accelerate the development of an injectable formulation of our
second-generation ASK1 inhibitor SRT-015 for ACLF, a liver disease
with high unmet need," said Neil
McDonnell, CEO of Seal Rock Therapeutics. "At Seal Rock, we
remain focused on initiating a Phase 2a trial of oral SRT-015 for
severe alcoholic hepatitis. We will also continue development of
our first-in-class LRRK2/ASK1 dual kinase inhibitors for
Parkinson's Disease and ALS."
"Considering its liver-centric activity, the potential for
multi-organ benefits and the breadth of evidence supporting further
development in ACLF, we strongly believe in the potential of
SRT-015," said Pascal Prigent,
CEO of GENFIT. "We are pleased to have this opportunity to develop
a new, injectable formulation of SRT-015 for Acute-on-Chronic Liver
Failure (ACLF)."
About SRT-015
SRT-015 is a second-generation inhibitor of ASK1 developed
internally by Seal Rock Therapeutics. Optimized to overcome the
liabilities of first-generation ASK1 inhibitors such as
selonsertib, and with a liver-preferential distribution, SRT-015 is
positioned as a first-in-class product candidate for NASH and
AH.
About Seal Rock Therapeutics
Seal Rock Therapeutics is a privately held, clinical stage
company based in Seattle focused
on developing first-in-class and best-in-class treatments for
severe diseases with limited or no available therapies.
Seal Rock is led by an experienced
management team with a track record of successful drug discovery,
development and commercialization. The company's clinical-stage
lead product candidate, SRT-015, is a highly optimized,
first-in-class ASK1 inhibitor. Seal
Rock is also developing preclinical-stage brain-penetrant
ASK1/LRRK2 dual kinase inhibitors for treatment of
neurodegenerative conditions such as Parkinson's disease and
ALS.
For more information, please visit www.sealrocktx.com
Media Contact:
Julie Rathbun
Rathbun Communications
Julie@rathbuncomm.com
206-769-9219
View original content to download
multimedia:https://www.prnewswire.com/news-releases/seal-rock-therapeutics-announces-out-licensing-agreement-with-genfit-for-development-of-injectable-formulation-of-srt-015-for-acute-on-chronic-liver-disease-aclf-301839273.html
SOURCE Seal Rock Therapeutics
